Cunningham Hit Ground Running When It Came To Tamping Down on Drug Prices

December 4, 2019 by Dan McCue
Cunningham Hit Ground Running When It Came To Tamping Down on Drug Prices

WASHINGTON – In the Lowcountry of South Carolina, Rep. Joe Cunningham’s race for Congress quickly became the stuff of local legend.

Here was a first-time candidate, a Democrat running in a staunchly Republican district, who defeated a well-financed GOP opponent, to become the first Democratic representative from South Carolina’s 1st Congressional District since 1981.

But the ever-energetic congressman didn’t stop there. Almost as soon as he arrived in Washington, at a time when many newcomers were still losing their way in the Capitol’s winding hallways, he was looking to fulfill some important campaign promises.

The first was filing a bill to ban offshore oil and gas exploration off the South Carolina coast. Soon thereafter, he actively joined efforts in the House to lower the cost of prescription drugs.

“One of my earliest constituent meetings was with Lowcountry parents who struggle to afford life-saving insulin for their children,” Cunningham recently said of the urgency he felt.

“In the last five years, the cost of one of the most common brands of insulin has increased from $2,907 a year to more than $4,700 a year. Meetings like these reaffirm to me how urgent this issue is,” he said.

In May, he voted in favor of H.R. 986, a bipartisan bill designed to strengthen protections for people with pre-existing conditions, an effort to buttress the Affordable Care Act against administration efforts to weaken it.

He followed up that vote, by introducing the CLAY Act, which would lower the cost of prescription drugs for beneficiaries who receive the low-income subsidy (LIS) in Medicare Part D.

More recently, Cunningham joined with fellow members of the Blue Dog Coalition of moderate House Democrats to endorse a series of prescription drug pricing bills that they believe, if taken up individually, could pass a Democratic-led House and a Republican-led Senate.

They include the CREATES Act and BLOCKING Act, bills aimed at helping generic drug makers bring their products to market more quickly while also lifting barriers to competition.

Cunningham told The Well News that when it comes to the issue of drug pricing, he expects meaningful results to be achieved, even against the headwinds of the ongoing impeachment proceedings and the impending 2020 political campaigns.

“Of course I do,” he said.

“My top priority in Congress is to serve the people of the Lowcountry and I know that my colleagues on both sides of the aisle feel the same way about their districts and their constituents,” Cunningham said.

“Lowering the cost of prescription drugs isn’t a Democratic or Republican issue – it’s an American one,” he added.

“Frankly, this issue is far beyond politics, this is about quality of life,” he said. “Nearly 3-in-10 South Carolinians have reported that they’ve had to stop taking medication as prescribed because of cost in the last year,” he said. “We need to get this legislation signed into law as soon as possible for them – and for folks across the nation.”

A+
a-
  • Joe Cunningham
  • prescription drug prices
  • In The News

    Health

    Voting

    Prescription Drugs

    May 12, 2025
    by Dan McCue
    Trump Moves to Lower Prescription Drug Prices

    WASHINGTON — President Donald Trump on Monday announced his intention to try to resurrect a controversial policy from his first... Read More

    WASHINGTON — President Donald Trump on Monday announced his intention to try to resurrect a controversial policy from his first administration in a bid to reduce the cost of some prescription drugs in the United States by linking their prices to those paid abroad. The policy,... Read More

    Pharmaceutical Industry Criticizes Drug Pricing Plan Trump Says He'll Sign

    WASHINGTON (AP) — President Donald Trump's plan to change the pricing model for some medications is already facing fierce criticism from the... Read More

    WASHINGTON (AP) — President Donald Trump's plan to change the pricing model for some medications is already facing fierce criticism from the pharmaceutical industry before he's even signed the executive order set for Monday that, if implemented, could lower the cost of some drugs. Trump has promised that... Read More

    April 18, 2025
    by Dan McCue
    Scores of Generic Medications Recalled Over Quality Issues

    WASHINGTON — Nearly 40 different generic medications have been voluntarily recalled by Glenmark Pharmaceuticals after regulators flagged issues related to... Read More

    WASHINGTON — Nearly 40 different generic medications have been voluntarily recalled by Glenmark Pharmaceuticals after regulators flagged issues related to how the drugs were manufactured in India, the Food and Drug Administration announced Friday. To ensure the safety and uniformity of medicines, the FDA has imposed... Read More

    Pfizer Ends Development of Potential Pill Obesity Treatment

    Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level... Read More

    Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver... Read More

    The Skyrocketing Cost of Weight-Loss Drugs Has State Medicaid Programs Looking for a Solution

    States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are searching for ways to... Read More

    States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are searching for ways to get out from under the budgetary squeeze that took them by surprise. One solution some policymakers may try is restricting the number of people on Medicaid... Read More

    FDA Approves Painkiller Designed to Eliminate the Risk of Addiction Associated With Opioids

    WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of... Read More

    WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or... Read More

    News From The Well
    scroll top